Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system (CNS) that might benefit from anti-inflammatory therapies. However, systemic delivery of anti-inflammatory drugs in MS patients has so far been disappointing, mostly due to the limited capacity of these molecules to enter the CNS. We injected into the cisterna magna (i.c.) of Biozzi AB/H mice affected by a relapsing-remitting form of experimental autoimmune encephalomyelitis (EAE), the animal model of MS, a non-replicative herpes simplex virus (HSV) type-1-derived vector containing the interleukin (IL)-4 gene (d120:LacZ:IL-4). CNS delivery of the d120:LacZ:IL-4 vector, after EAE onset, induced the in situ production of IL-4 by CNS-resident cells facing the cerebrospinal fluid (CSF) spaces and reduced by 47% (P Ͻ 0.02) the disease-related deaths. Compared with mice treated with the control d120:LacZ vector, IL-4-treated mice also showed a shorter duration of the first EAE attack, a
Introduction
The pathological hallmark of multiple sclerosis (MS) is the presence, within the central nervous system (CNS), of patchy perivascular leukocyte infiltrates leading to demyelination and axonal loss. 1 It is currently believed that T cells specific for CNS antigens (ie myelin components) provide the organ specificity of the pathogenic process and contribute in regulating the recruitment within the CNS of effector cells, including monocytes/macrophages. 2 Pro-inflammatory cytokines (ie Th1 cytokines) are believed to play a crucial role in this pathogenic process since they can promote and sustain the development of myelin-specific T cells and promote the recruitment, within the CNS, of peripheral myelinotoxic effector cells (ie monocyte/macrophages). 3 In addition, pro-inflammatory cytokines such as tumor longer inter-relapse period, and a reduction in the severity and duration of the first relapse. Protection from EAE progression in IL-4-treated mice was associated with activation of microglia in spinal cord areas where mRNA content of the pro-inflammatory chemokines, macrophage chemoattractant protein-1 (MCP-1) and Rantes, was reduced and that of the anti-inflammatory cytokine IL-4 was increased. Finally, CNSinfiltrating mononuclear cells from IL-4-treated mice produced lower levels of MCP-1 mRNA compared with control mice. Our results, showing that IL-4 gene delivery using HSV-1 vectors induces protection from EAE by in situ modulating the cytokine/chemokine-mediated circuits sustaining effector cell functions, indicate that the intrathecal 'therapeutic' use of nonreplicative HSV-1-derived vectors containing anti-inflammatory molecules might represent an alternative strategy in inflammatory diseases of the CNS. Gene Therapy (2001) 8, 13-19. necrosis factor (TNF)␣ can be directly toxic for oligodendrocytes. 4 Pro-inflammatory cytokines thus represent a suitable therapeutic target in MS. However, systemic delivery of anti-inflammatory cytokines (ie Th2 cytokines) has showed limited, or no, efficacy and considerable toxicity when administered to MS patients. Intramuscular or subcutaneous administration of interferon (IFN)␤ reduces by only one third the exacerbation rate of the disease, does not change substantially the progression of disability and induces the production of neutralizing anti-IFN␤ antibodies. 5, 6 Systemic administration of transforming growth factor (TGF)␤ fails to prevent the appearance of new inflammatory magnetic resonance imaging lesions in the brain of patients and causes reversible nephrotoxicity. 7 Intravenous injection of the recombinant TNF-receptor p55 immunoglobulin fusion protein Lenercept increases the number of patients experiencing disease relapses and induces the formation of neutralizing antibodies. 8 These disappointing results are possibly due to the scarce capacity of systemically administered cytokines to cross the blood-brain barrier (BBB) and accumulate in the CNS where the MS pathogenic process takes place. 9 Moreover, cytokines act in an autocrine-paracrine fashion and have a short half-life thus being consumed at the site of production and/or administration. The CNS delivery of anti-inflammatory cytokines could partially overcome these limitations. Biological and nonbiological vectors engineered with heterologous genes coding for anti-inflammatory cytokines and injected into the CNS might represent appropriate tools to deliver 'protective' molecules in inflammatory demyelinating diseases of the CNS. 10 We have recently developed a novel system to deliver cytokine genes into the CNS based on the use of HSV type-1-derived non-replicative vectors. 11 We showed that HSV-1 vectors containing cytokine genes, when injected within the CNS via the intracisternal (i.c.) route, diffuse consistently in all cerebrospinal fluid (CSF) spaces and are able to infect efficiently the layer of choroidal, ependymal, and leptomeningeal cells surrounding these spaces. Within the CNS, vectors redirect the cell machinery of infected CNS-resident cells to produce discrete amounts of the bioactive form of the cytokine encoded by the transgene into the CSF of mice for almost 1 month after injection without causing any CNS and/or peripheral side-effect. 11 We now report that i.c. injection of an HSV-1-derived vector, containing the gene of the prototypic anti-inflammatory cytokine IL-4 (d120:LacZ:IL-4), in Biozzi AB/H mice with established EAE inhibits disease progression and protects mice from EAE-related mortality. This protective effect is associated with in situ modification of the cytokine/chemokine milieu sustaining demyelinating mechanisms.
Results
HSV-1-derived non-replicative vectors infect cells surrounding ventricular and subarachnoid spaces when i.c. injected Naive Biozzi AB/H mice were i.c. injected with the IL-4-producing vector (d120:LacZ:IL-4) or the control vector containing the LacZ gene only (d120:LacZ) and then killed 72 h, 1 week or 2 weeks after injection. Vectors distributed in all ventricular and subarachnoid spaces either rostrally or caudally to the site of injection, efficiently infected choroidal, ependymal and leptomeningeal cells but did not reach the CNS parenchima. IL-4 was detected in choroidal ( Figure 1A ), ependymal ( Figure 1B ) and leptomeningeal cells from mice injected with the d120:IL-4:LacZ but not in CNS tissue sections from mice injected with the d120:LacZ control vector ( Figure 1C ). IL-4 was never found in neuronal cells after i.c. injection of the d120:IL-4:LacZ (Figure 1 ). The vector infection of CNSresident cells facing the CSF spaces did not induce any sign of vector toxicity; no lymphomononuclear cell infiltration and/or cell degeneration were found around ventricular and subarachnoid areas (Figure 1 ).
I.c. injection of the HSV-1-derived non-replicative IL-4-producing vector halts EAE progression and prevents EAE-related mortality Biozzi AB/H mice were immunized with spinal cord homogentate (SCH) and i.c. injected at the time of EAE onset (day 0) with 10 7 p.f.u. per mouse of the d120:Lac-Z:IL-4 or of the d120:LacZ vector. Before vector injection mice were randomized into two treatment groups accord- ing to the EAE clinical score. Clinical data are summarized in Table 1 . EAE mortality rate among mice injected with the d120:LacZ vector (thereafter referred to as control mice) was 47% (nine of 19), while none of the 12 mice injected with the d120:LacZ:IL-4 vector (thereafter referred to as IL-4-treated mice) died (P Ͻ 0.02) ( Table 1 , Figure 2a ). The first day after vector injection (day 1) IL-4-treated mice were clinically stable (EAE score from 1.8 at day 0 to 2.1 at day 1) while control mice worsened significantly (EAE score from 1.9 at day 0 to 3.2 at day 1; P Ͻ 0.02) (Figure 2b ). The difference between the two groups was still evident on days 2 (P Ͻ 0.05) and 3, and a Treatment was performed in each mouse by injection on the day of EAE onset of 10 7 p.f.u. of the IL-4-containing HSV-1-derived vector (d120:LacZ:IL-4) or the control vector (d120:LacZ). b EAE onset is expressed as day after immunization ± s.e. c EAE score is expressed as mean maximum score ± s.e. d P Ͻ 0.01 versus d120:LacZ-treated mice. e The incidence of the first relapse is reported instead of the mortality.
Figure 2 Clinical characteristics of EAE in Biozzi AB/H mice immunized with SCH and i.c. injected with the d120:IL-4:LacZ vector and the d120:LacZ control vector. Panel a shows the maximum EAE score in individual mice treated with the IL-4-containing vector (open circles) or with the control vector (closed circles). The mean maximum EAE score (indicated by the line) is significantly different between the two groups (*P Ͻ 0.01). Panel b shows the mean EAE score in mice treated with the d120:IL-4:LacZ vector (open circles) and the d120:LacZ control vector (closed circles) in the 15 days following the i.c. injection of the vectors. The EAE score was identical between the two groups at the time of vector injection (day 0), the first day of appearance of EAE signs and symptoms. The difference between the two groups is statistically significant for the first 3 days after treatment (*P Ͻ 0.05).
the recovery from this first attack was more rapid in the IL-4-treated mice (13 days) compared with controls (16 days) (Figure 2b ).
During the follow-up period, two of four (50%) mice in both the IL-4-treated and control groups experienced relapse. However, relapse onset was delayed (45.5 ± 4.5 versus 34.0 ± 5.0 days from disease onset) and relapse duration (4.5 ± 1 versus 18.0 ± 6.0 days) and severity (1.2 ± 0.2 versus 3.2 ± 0.7 maximum EAE score; 4.75 ± 1.2 versus 39.2 ± 1.2 cumulative EAE score; P Ͻ 0.005) were significantly reduced in the IL-4-treated compared with control mice (Table 1) .
IL-4 gene delivery decreases spinal cord mRNA levels of MCP-1 and Rantes and increases that of IL-4
The cytokine/chemokine mRNA expression pattern was measured 72 h after vector injection into the spinal cord of three mice treated with the d120:LacZ:IL-4 vector and of three mice treated with the d120:LacZ vector. At the time of death, all mice were experiencing the first attack of EAE and showed spinal cord symptoms typical of the disease such as caudo-cranial ascending paralysis. 
IL-4 gene therapy activates microglia
To evaluate and quantify the neuropathological changes induced by the IL-4 gene therapy, we analyzed spinal cord pathology of three EAE mice treated with the d120:LacZ:IL-4 vector and of three EAE mice treated with the d120:LacZ vector 72 h after vector injection.
The mean number of inflammatory infiltrates (± s.e.) was similar between IL-4-treated mice (5.0 ± 1.1 per mm 2 ) and control mice (5.9 ± 0.5 per mm 2 ) (Figure 3 ). The mean number of CNS-infiltrating macrophages, decorated either with MAC-1 antibody (Figure 3a 
Discussion
Here, we show that CNS administration of an IL-4 genecontaining HSV-1-derived non-replicative vector halts the progression of relapsing-relapsing EAE when administered to Biozzi AB/H mice after disease onset. The IL-4 gene therapy protocol determined: (1) a significant reduction of the number of EAE-related deaths; (2) a shortened duration of the first attack; (3) a longer interrelapse period; and (4) a decreased severity and duration of the second relapse. The protective effect of IL-4 in EAE is not surprising. Systemic administration of IL-4 to myelin basic protein (MBP)-immunized mice induced a shift towards MBPspecific Th2 cells 13 and/or TGF␤-secreting cells 14 leading to decreased CNS levels of inflammatory cytokine and of demyelination. Anti-IL-4 antibody administration reverted protection from EAE obtained by tolerization with altered peptide ligands of encephalitogenic MBP 87-99 specific T cell clones. 15 In these previous studies, however, IL-4 was administered only systemically and before EAE onset, thus explaining that the protective effect of IL-4 was observed on peripheral regulatory T cells (ie Th1 versus Th2 cell shift), rather than on CNS-resident 'effector' cells. Here we show that IL-4 can also inhibit ongoing EAE through a mechanism exerted at CNS level. We found that IL-4-treated mice had (1) reduced spinal cord mRNA levels of pro-inflammatory chemokines such as MCP-1 and Rantes; (2) increased spinal cord mRNA levels of the anti-inflammatory cytokine IL-4; and (3) decreased mRNA level of MCP-1 in CNS-infiltrating mononuclear cells. Moreover, the in situ effect of our gene therapy protocol is also supported by the fact that we showed that CNS administration of the d120:LacZ:IL-4 vector determined a specific and exclusive infection of ependymal and choroidal cells that, in turn, secreted IL-4 into the CSF. Furthermore, we previously demonstrated that i.c. delivery of the d120:LacZ:IL-4 vector does not induce blood leak of IL-4 and does not influence peripheral immune system functions such as antigen presentation, T cell activation and cytokine secretion. 11 However, 72 h after CNS delivery of the IL-4 gene we did not observe any significant reduction of the number of CNS-infiltrating mononuclear cells, and in particular, of macrophages that are considered the ultimate effector cells in EAE. 16, 17 How can we explain this apparent paradox? One likely explanation is that macrophage recruitment might be impaired later on as suggested by the fact that in IL-4-treated mice the first relapse was consistently less severe. Another likely explanation is that CNS delivery of IL-4 may induce a 'protective' in situ activation of microglia that, in turn, limits CNS inflammation. 18 In the spinal cord of IL-4-treated mice we found: (1) a significant increase of the number of activated microglia-like cells; (2) a consistent increase of IL-4 level; and (3) a decrease in the transcription rate of pro-inflammatory chemokines (MCP-1 and Rantes). Our data showing that activation of microglia is associated with a down-regulation of the cytokine/chemokine pro-inflammatory milieu leading to the inflammatory process sustaining EAE progression support the role of activated microglia in limiting CNS inflammation. This hypothesis is also confirmed by the recent findings that IL-4 inhibits the production of TNF␣ and IL-1␤ that, in turn, inhibits MCP-1 production 19 and that both TNF␣ and MCP-1 (secreted either by mononuclear cells or glial cells) are crucial molecules in the acute phase of inflammatory diseases such as EAE because they can facilitate the massive transmigration of inflammatory cells through the BBB.
19-21
Accordingly, we found a trend (although not statistically significant possibly due to the low number of mice tested) toward the decrease of the mRNA content of TNF␣ and IL-1␤ in the spinal cord of IL-4-gene therapytreated mice. Furthermore, the protective effect on EAE of a potent inhibitor of matrix metalloproteinases was associated with the increased expression of IL-4 in microglia-like cells and astrocytes. 22 IL-4 induces proliferation and activation of microglia but still suppresses IFN␥-induced class II MHC antigen expression in the same cells. 23 Glial cells, in vitro stimulated with IL-4, produce anti-inflammatory cytokines such as IL-1 receptor antagonist as well as neuroprotective agents such as nerve growth factor (NGF). 24, 25 Finally, IL-4 can also activate dendritic cells in choroid plexus epithelium to act as immunosuppressive cells by producing IL-10. 26 On the other hand, there are data indicating that activated microglia may limit CNS inflammation by re-stimulating in situ 'anti-inflammatory' Th2 responses. 21 Although we recorded an increased number of CNSinfiltrating T cells in IL-4-treated versus control mice, we can exclude the possibility that the protective effect of IL-4 was due to an increased recruitment of Th2 'protective' T cells since we did not observe changes in mRNA levels of Th1 (ie TNF␣) and Th2 (ie IL-4) cytokines 27 in CNSinfiltrating cells from IL-4-treated versus control mice.
In conclusion, the delivery in EAE of the IL-4 gene using HSV-1-derived non-replicative vectors was therapeutically effective and showed a rapid (Ͻ72 h after injection) and persistent (4 weeks) effect after a single vector administration. The therapeutic efficacy of this protocol, along with the possibility of accommodating multiple genes within HSV-1-derived vectors, suggests that this therapeutic approach might be useful to deliver anti-inflammatory molecules with synergistic activity in inflammatory diseases of the CNS. However, disadvantages of the present technology have yet to be solved. The relatively time-limited cytokine production (up to 4 weeks after in vivo vector-mediated delivery) as well as the inability to regulate gene transcription are still major limiting factors for the applicability of the present technology to chronic diseases such as MS.
Materials and methods

Mice
Biozzi AB/H female mice, 6-8 weeks of age, were obtained from Harlan UK Limited (Bicester, UK). Mice were housed in specific pathogen-free conditions, allowing free access to food and water. All procedures involving animals were performed according to the guidelines of the Animal Ethical Committee of our Institute (IACUC).
HSV-1-derived vectors and vector injections
Viral constructs have been previously described. 11, 28 Briefly, the IL-4 gene-containing vector accommodates the Escherichia coli Lac-Z gene driven by the human CMV immediate-early promoter and the mouse IL-4 gene driven by the infected cell protein (ICP)4 promoter (d120:IL-4:LacZ vector); the control vector was identical to the d120:IL-4:LacZ but contained only the Lac-Z gene (d120:Lac-Z vector). Expression cassettes containing the heterologous genes (ie LacZ, IL-4) were inserted in both vectors into the thymidine kinase locus on an ICP4-defective HSV-1 virus (d120) that was propagated on a compGene Therapy lementing cell line (E5). 28 HSV-1 stocks were diluted with complete DMEM (supplemented with 10% FCS) to obtain 1 × 10 9 p.f.u./ml. Ten l (1 × 10 7 p.f.u.) of the vectors were injected into the cisterna magna (i.c.) of mice, as previously described.
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EAE induction and treatment EAE was induced by subcutaneous immunization into the flanks with 2 mg of spinal cord homogenate (SCH) in IFA (Difco, Detroit, MI, USA) supplemented with 4 mg/ml of Mycobacterium tuberculosis (strain H37Ra; Difco). Immunization was performed in each mouse twice, 7 days apart, as previously described. 12 Mice received 500 ng of pertussis toxin (Sigma, St Louis, MO, USA) i.p. at the time of the immunization and 48 h later. Weight and clinical score (0 = healthy, 1 = flaccid tail, 2 = ataxia and/or paresis of hindlimbs, 3 = paralysis of hindlimbs and/or paresis of forelimbs, 4 = tetraparalysis, 5 = moribund or death) were recorded daily. Twenty-one Biozzi AB/H mice were i.c. injected on the day of clinical EAE onset with the d120:IL-4:Lac-Z vector (IL-4-treated mice) and 28 mice with the d120:Lac-Z control vector (control mice). Nine mice in each group were killed 72 h after treatment for neuropathological examination, spinal cord RNA extraction, and recovery of CNS-infiltrating cells (three mice for each procedure). Clinical data are the cumulative result of three independent experiments.
Recovery of infiltrating cells from the CNS of EAE mice CNS-infiltrating cells were recovered from the whole CNS of EAE mice as previously described. 29 Briefly, CNS tissue was homogenized with a potter in saline and then pelletted by centrifugation at 400 g for 10 min. One ml 100% Percoll (Pharmacia, Uppsala, Sweden, diluted 9:1 v/v with 10× PBS), 2 ml 80% Percoll, 3 ml 40% Percoll, and 2 ml 30% Percoll in PBS were stratified on the pellet. After centrifugation at 400 g for 10 min, cells were recovered from the interface between the 40% and 80% Percoll layers, washed several times, resuspended and counted. An average of 70 000-100 000 cells were obtained from each CNS.
RNAse protection assay (RPA) Total RNA was prepared from the spinal cords of mice using RNAfast (Molecular Systems, San Diego, CA, USA) according to the manufacturer's instructions. Five g of each RNA sample was processed with a commercially available multi-probe RNAse protection assay system (RiboQuant; Pharmingen, San Diego, CA, USA) for mouse chemokines (lymphotactin, Rantes, eotaxin, MIP-1␣, MIP-1␤, MIP-2, IP-10, MCP-1, TCA-3) and chemokine receptors (CCR1, CCR1b, CCR3, CCR4, CCR5, CCR2), following the manufacturer's instructions. Riboprobe sets were synthesized using ␣-32 UTP (Amersham Life Science, Cologno Monzese, Milan, Italy). Protected bands were resolved on 5% acrylamide gel and intensity of the signals analyzed on Phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA; Image Quant Software, version 3.3), normalized against the intensity of GAPDH protected bands and expressed as arbitrary units.
Semi-quantitative RT-PCR
Total RNA (extracted as described before) was tested for cytokine and chemokine transcript levels by semiquantitative RT-PCR in CNS-infiltrating mononuclear cells (IL-4, TNF-␣, MCP-1) and spinal cords (IL-1␤, TNF-␣, IL-1ra, IL-4, MCP-1) from IL-4-treated and control mice. cDNA synthesis, PCR amplification, and detection of amplified products were performed as previously described. 30 The following primers and probes were used: IL-1␤ (product: 563 bp), antisense 5′-CAG GAC AGG TAT AGA TTC TTT CCT TT-3′, sense 5′-ATG GCA ACT GTT CCT GAA CTC AAC T-3′, probe 5′ AGC TTT CAG CTC ATA TGG GTC CGA CAG CAC 3′; IL-4 (product 181 bp), antisense 5′ GAC TCA TTC ATG GTG CAG CTT ATC G 3′, sense 5′ CGA AGA ACA CCA CAG AGA GTG AGC T 3′; TNF␣ (product: 373 bp), antisense 5′-GTA TGA GAT AGC AAA TGC GCT GAC GGT GTG GG-3′, sense 5′-TTC TGT CTA CTG AAC TTC GGG GTG ATC GGT CC-3′, probe 5′ GCC GTT CCG CAG GAG GGC GTT GGC GCG CTG 3′; MCP-1 (product 535 bp), antisense 5′ CTG CTG CTA CTC ATT CAC CA 3′, sense 5′ TTA CCC ATT CAT CTT TAC AA 3′, probe 5′ CCA GCA GCA GGT GTC CCA AAG AAG C 3′; GAPDH (product: 710 bp), antisense 5′-CGC ATC TTC TTG TGC AGT G-3′; sense 5′-GTT CAG CTC TGG GAT GAC-3′. Values were normalized against the GAPDH gene. RT-PCR results were expressed as arbitrary units.
Neuropathology of EAE mice
At the time mice were killed they were transcardially perfused with 4% paraformaldhyde. Brains and spinal cords were removed and embedded in paraffin. Tissue sections were cut at 4 m and stained with H&E, Luxol fast Blue and Bielshowsky stain to detect inflammatory infiltrates, demyelination and axonal loss, respectively. T cells were stained using a rat anti-CD3 (pan-T cell marker; Serotec Ltd, Oxford, UK) revealed with a biotin-labeled secondary anti-rat antibody (Amersham) while macrophages and microglia-like cells with a peroxidase-labeled rat anti-MAC-1 (Boehringer, Mannheim, Germany) antibody revealed with a biotin-labeled secondary anti-rat antibody (Amersham). Macrophages were also stained with BS-I isolectin B4 (Sigma, St Louis, MO, USA) revealed with a biotin-labeled secondary anti-rat antibody (Amersham). Mouse IL-4 was revealed using a rat antimouse IL-4 antibody (Pharmingen) followed by a biotinlabeled secondary anti-rat antibody (Amersham).
MAC-1 + microglia-like cells were differentiated from macrophages on the basis of their morphological features (ie cell bodies connected with ramified processes). Neuropathological findings were quantified on an average of 10 complete cross-sections of spinal cord per mouse. The number of perivascular inflammatory infiltrates was calculated and expressed as the numbers of inflammatory infiltrates per mm 2 , demyelinated areas and axonal loss were expressed as the percentage of damaged area per mm 2 . T cells, macrophages and microglia-like cells were counted and expressed as number of cells per mm 2 , as previously described.
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Statistical analysis EAE scores, RT-PCR, RPA, and neuropathological results have been compared using Student's t test for unpaired data, mortality rates using the 2 test. P values р0.05 were considered statistically significant.
